Bolivia approved China COVID-19 Vaccine
- Subversive discovery: Can lymph nodes promote the success of cancer immunotherapy?
- Major Discovery: Cancer cell PD-L1 does not inhibit T cell toxicity
- The new coronavirus may kill cancer cells and achieve a permanent cure!
- Why did the Alzheimer’s drug candidate BACE1 inhibitor fail?
- LRTI Death: Research spanning 80 years confirms for the first time
- The decline of the global antibiotic market is threatening the development of new drugs
Bolivia approved China COVID-19 Vaccine
Bolivia approved China COVID-19 Vaccine. On the night of February 11, the signing ceremony of Sinopharm and Bolivia’s new coronavirus vaccine cooperation was held in Beijing and La Paz in the form of a video conference.
Bolivian President Luis Arce said in his speech that it is the friendship between China and Bolivia that allows us to obtain the Sinopharm Sinopharm vaccine at this moment. This month, Bolivia was able to start a large-scale immunization of the COVID-19 vaccine to benefit the people of Bolivia as soon as possible. It is certain that this vaccine will make a great contribution to the health of the people of Bolivia. This is a common journey, and this cooperation ceremony fulfilled the commitment of China and Bolivia to cooperate in jointly deepening the fight against the epidemic. Pay tribute to the people in China who have made efforts and contributions to the people of Bolivia and Bolivia to obtain vaccines.
Liu Jingzhen, Chairman of Sinopharm Group, said in his speech that under the guidance and support of the Ministry of Foreign Affairs of China and other ministries and commissions, and under the personal promotion of President Arce, the National Bureau of Medicines and Health Technology of Bolivia has officially approved the registration and listing of Sinopharm’s China Bio-COVID-19 Vaccine.
This is our full trust in the safety and effectiveness of our vaccines, and it is also a concrete action to implement the consensus of the two heads of state, opening a new chapter in the cooperation between the two countries in the field of life and health, especially biomedicine. It is believed that Sinopharm China Bio-COVID-19 Vaccine will provide strong support for the prevention and control of the epidemic in Bolivia and build a solid health barrier for the people of Bolivia.
Chinese Ambassador to Bolivia Huang Yazhong said in his speech that this cooperation has witnessed the friendship between the two countries and is also a practice for us to build a community with a healthy future for mankind. Human beings may be small for the earth, but if all nations and nationalities unite together, they are very powerful. At present, all countries in the world are facing the current situation of vaccine shortage, and it is not easy for us to achieve the result of today’s signing ceremony through our efforts. It will be the Lunar New Year soon, so take this opportunity to express your wishes for the new year. It is hoped that in the new year, the friendship between the two governments and the two peoples can reach a higher level through cooperation.
The Minister of Health and Sports of Bolivia, Jason Marcos Oza Pinto, said in his speech that today’s signing ceremony has witnessed that we are able to obtain more effective tools in the fight against the epidemic, which is the most effective of all the means to fight the COVID-19 epidemic. It is a vaccine. Through our own efforts and international assistance, it has become a reality to enable the people of Bolivia to obtain economic and effective vaccines and defeat the COVID-19 epidemic. This is thanks to the work of our domestic and foreign professionals and partners day and night, and their dedication and commitment to Bolivia’s fight against the epidemic.
China Biotech Chairman Yang Xiaoming, Sinopharm International Hong Kong Company Li Guangfa, Beijing Biological Products Research Institute Deputy General Manager Wang Xiaojie, and Bolivia Health Products and Supply Center Director Victor Hugo jointly signed a COVID-19 vaccine cooperation agreement.
The signing ceremony was presided over by Womi, an official of the Bolivian Presidential Palace. Bolivian Vice President David Joquinca Cespedes, Foreign Minister Rogerio Mehta, and Deputy Minister of Foreign Trade and Integration Benjamin Blanco Fei Here, Shi Shengyi, Deputy General Manager of Sinopharm Group, Zhu Jingjin, Secretary of the Party Committee of Sinopharm, Li Can, General Manager of Sinopharm International, Li Chunsheng, Secretary of the Party Committee, and Yan Bing, Deputy General Manager attended the signing ceremony.
The Bolivian National Agency for Medicines and Health Technology approved the official registration and marketing of the COVID-19 inactivated vaccine of the Beijing Institute of Biological Products of Sinopharm Group on February 5. This is an important measure for Bolivia to fight the COVID-19 epidemic. At the same time, Bolivia has also become the third overseas country to officially approve the listing of Sinopharm’s China Bio-COVID-19 Vaccine after the UAE and Bahrain, and it is also the first South American country to approve the listing.
Sinopharm’s China Bio-COVID-19 Inactivated Vaccine was approved to be marketed conditionally in China on December 30, 2020, and more than 30 million key populations have been vaccinated. The COVID-19 vaccine was approved for registration and marketing in the UAE, Bahrain, and Bolivia on December 9, 2020, December 13, and February 5, 2020. It has been vaccinated or used in emergency in 20 countries around the world.
More than 10 leaders of state and politicians have been vaccinated with Sinopharm’s China Bio-COVID-19 Vaccine. The technical safety, protective effectiveness, population applicability, capacity accessibility, and convenience of storage and transportation of the vaccine have been highly recognized by the international community. At present, Sinopharm Sinopharm has established high-grade biosafety production workshops for the COVID-19 inactivated vaccines in Beijing and Wuhan, which have been put into large-scale production, and the production capacity can reach more than 1 billion doses in 2021.
(source:internet, reference only)
Disclaimer of medicaltrend.org